Suzhou Junjing Biosciences Co., Ltd.

This study is testing whether adding a new drug called WJ01024 to an existing medication (ruxolitinib) can help people with intermediate- or high-risk myelofibrosis, especially those whose disease hasn't responded well to prior JAK inhibitor treatments. The main goals are to see …